Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05640245 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
A Phase 2 study of Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
- 20
- Study locations
NCT05640245 is a Phase 2 study of Arthritis, Psoriatic that has completed, run by MoonLake Immunotherapeutics. The registered enrollment target is 207 participants, below the 563-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT05640245, a Phase 2 study of Arthritis, Psoriatic, has completed, sponsored by MoonLake Immunotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis. The study includes adalimumab treatment as an active reference arm.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Adalimumab
- DRUG Sonelokimab
Study Locations (20)
Other
- Clinical Site - Pleven
- Clinical Site - Pleven
- Clinical Site - Plovdiv
- Clinical Site - Plovdiv
- Clinical Site - Rousse
- Clinical Site - Sofia
- Clinical Site - Stara Zagora
- Clinical Site - Varna
- Clinical Site - Ostrava
- Clinical Site - Tallinn
- Clinical Site - Tartu
- Clinical Site - Hamburg
- Clinical Site - Herne
- Clinical Site - Budapest
- Clinical Site - Budapest
- Clinical Site - Budapest
- Clinical Site - Szentes
- Clinical Site - Székesfehérvár
California
- Clinical Site - Rancho Mirage
Pennsylvania
- Clinical Site - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2024-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05640245
The ClinicalTrials.gov registry entry for NCT05640245 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 563-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (63% lower). The listed sponsor is MoonLake Immunotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05640245 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05640245 about?
NCT05640245 is a clinical study titled "Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis". This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis. The study includes adalimumab treatment as an active reference arm.
What is the current status of trial NCT05640245?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2022-12-13. Estimated completion is 2024-01-15.
What conditions does trial NCT05640245 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT05640245?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG), Sonelokimab (DRUG).
Who is sponsoring clinical trial NCT05640245?
This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05640245 being conducted?
This trial has 20 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
RECRUITING · Phase 2
-
Low Dose Naltrexone for Chronic Pain From Arthritis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.